The authors wish to make the following correction to this paper [1]:
In the first paragraph of the Results section: “P1 and P2 started ERT with elosulfase alfa (VIMIZIM® by BioMarin©) 5 months post-diagnosis at age 4.5 years and 11 months, respectively, with an intravenous dose of 1.0 mg/kg/week.” The value of the dose is 1.0 mg/kg/week but should be corrected to 2.0 mg/kg/week.
These changes have no material impact on the conclusions of our paper. We apologize to our readers.
Reference
- Barak, S.; Anikster, Y.; Sarouk, I.; Stern, E.; Eisenstein, E.; Yissar, T.; Sherr-Lurie, N.; Raas-Rothschild, A.R.; Guttman, D. Long-Term Outcomes of Early Enzyme Replacement Therapy for Mucopolysaccharidosis IV: Clinical Case Studies of Two Siblings. Diagnostics 2020, 10, 108. [Google Scholar] [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).